drugset / Trial / NCT05486468
The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment
Phase 3
Completed
10 enrolled
Texas Retina Associates
ANI Pharmaceuticals · collabEyePoint Pharmaceuticals, Inc. · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The Use of Two YUTIQ versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment (TYNI Trial)
Timeline
- Start
- 2022-10-05
- Primary completion
- 2026-03-31
- Completion
- 2026-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | fluocinolone acetonide | Other / unclassified | 0.18 mg | Intravitreal |